Medications for Myelodysplastic Syndromes

29 results

  • Azacitidine (azacitidine)

    (AZACITIDINE)
    Eugia US LLC
    Usage: Azacitidine for injection is indicated for treating adult patients with specific myelodysplastic syndrome subtypes, including refractory anemia, refractory anemia with ringed sideroblasts (with complications), refractory anemia with excess blasts, and chronic myelomonocytic leukemia. Pediatric use is not labeled due to marketing exclusivity.

  • Azacitidine (azacitidine)

    (azacitidine)
    Wockhardt USA LLC.
    Usage: Azacitidine for injection is indicated for treating myelodysplastic syndromes (MDS), including refractory anemia (with or without ringsideroblasts), refractory anemia with excess blasts, and chronic myelomonocytic leukemia (CMMoL).

  • Azacitidine (azacitidine)

    (Azacitidine)
    Cipla USA Inc.
    Usage: Azacitidine for injection is indicated for adult patients with myelodysplastic syndromes (MDS), specifically subtypes such as refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia.

  • Azacitidine (azacitidine)

    (azacitidine)
    Sandoz Inc
    Usage: Azacitidine for injection is indicated for treating adult patients with certain subtypes of myelodysplastic syndromes (MDS) and for pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML).

  • Azacitidine (azacitidine)

    (Azacitidine)
    Dr. Reddy's Laboratories Inc.
    Usage: Azacitidine for injection is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), specifically refractory anemia, refractory anemia with ringed sideroblasts (with certain conditions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

  • Decitabine (decitabine)

    (decitabine)
    Sagent Pharmaceuticals
    Usage: Decitabine for Injection is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including all French-American-British subtypes and various risk groups, whether previously treated or untreated, as well as de novo and secondary MDS, including chronic myelomonocytic leukemia.

  • Decitabine (decitabine)

    (Decitabine)
    Novadoz Pharmaceuticals LLC
    Usage: Decitabine for injection is indicated for treating adult patients with myelodysplastic syndromes (MDS), including all subtypes, both previously treated and untreated, as well as chronic myelomonocytic leukemia in various risk groups according to the International Prognostic Scoring System.

  • Decitabine (decitabine)

    (decitabine)
    Gland Pharma Limited
    Usage: Decitabine for Injection is indicated for adult patients with myelodysplastic syndromes (MDS), including all French-American-British subtypes and varying risk groups, regardless of prior treatment status.

  • Grafapex (treosulfan)

    (treosulfan)
    Medexus Pharma, Inc.
    Usage: GRAFAPEX is indicated, in combination with fludarabine, as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients aged 1 year and older with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

  • Lenalidomide (lenalidomide)

    (Lenalidomide)
    Biocon Pharma Inc.
    Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.